| Abstrakt: |
Researchers from Betta Pharmaceuticals Co. Ltd. have submitted a patent application for a bispecific antibody targeting GARP, TGF-b, and PD-L1 to inhibit immunosuppression and reactivate immune responses to cancer cells. This antibody aims to enhance tumor killing and has shown promise in clinical trials for various cancers. The development of bispecific antibodies is a rapidly advancing field with potential applications in tumor treatment and autoimmune diseases, although further improvements are needed for targeting different entities effectively. [Extracted from the article] |
